An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 021929
Company: ASTRAZENECA

Other Important Information from FDA

Products on NDA 021929

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
SYMBICORT	BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE	0.08MG/INH;0.0045MG/INH	AEROSOL, METERED;INHALATION	Prescription	AB	Yes	Yes
SYMBICORT	BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE	0.16MG/INH;0.0045MG/INH	AEROSOL, METERED;INHALATION	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 021929

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
07/21/2006	ORIG-1	Approval	Type 4 - New Combination	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021929lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021929ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021929_symbicort_toc.cfm

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
12/20/2017	SUPPL-42	Efficacy-Labeling Change With Clinical Data	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021929s042lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/021929Orig1s042ltr.pdf
09/11/2017	SUPPL-41	Efficacy-Labeling Change With Clinical Data	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021929s041lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/021929Orig1s041ltr.pdf
06/10/2016	SUPPL-40	Manufacturing (CMC)		Label is not available on this site.
06/28/2014	SUPPL-39	Manufacturing (CMC)		Label is not available on this site.
04/14/2015	SUPPL-38	Manufacturing (CMC)		Label is not available on this site.
04/04/2014	SUPPL-37	Manufacturing (CMC)		Label is not available on this site.
02/27/2014	SUPPL-36	Manufacturing (CMC)		Label is not available on this site.
01/15/2014	SUPPL-35	Manufacturing (CMC)		Label is not available on this site.
07/23/2012	SUPPL-33	REMS-Modified	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/021929Orig1s033ltr.pdf
05/08/2012	SUPPL-30	Labeling-Medication Guide		Label is not available on this site.
08/18/2011	SUPPL-28	REMS-Modified	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021929s028ltr.pdf
06/25/2010	SUPPL-21	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021929s021lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/021929s021ltr.pdf
02/16/2011	SUPPL-19	REMS-Assessment, REMS-Modified	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021929s019ltr.pdf
01/27/2017	SUPPL-13	Efficacy-New Patient Population	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021929s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/021929Orig1s013ltr.pdf
02/27/2009	SUPPL-12	REMS-Proposal, Efficacy-New Indication	Label (PDF) Letter (PDF) Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021929s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021929s012ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021929Orig1s012.pdf
07/16/2008	SUPPL-10	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021929s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021929s010ltr.pdf
10/26/2007	SUPPL-6	Manufacturing (CMC)-Control	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021929s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021929s006ltr.pdf
10/31/2007	SUPPL-4	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021929s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021929s004ltr.pdf

Labels for NDA 021929

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
12/20/2017	SUPPL-42	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021929s042lbl.pdf
09/11/2017	SUPPL-41	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021929s041lbl.pdf
01/27/2017	SUPPL-13	Efficacy-New Patient Population	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021929s013lbl.pdf
06/25/2010	SUPPL-21	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021929s021lbl.pdf
02/27/2009	SUPPL-12	REMS-Proposal	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021929s012lbl.pdf
02/27/2009	SUPPL-12	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021929s012lbl.pdf
07/16/2008	SUPPL-10	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021929s010lbl.pdf
10/31/2007	SUPPL-4	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021929s004lbl.pdf
10/26/2007	SUPPL-6	Manufacturing (CMC)-Control	Label (PDF)	This supplement type does not usually require new labeling.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021929s006lbl.pdf
07/21/2006	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021929lbl.pdf

Therapeutic Equivalents for NDA 021929

SYMBICORT

AEROSOL, METERED;INHALATION; 0.08MG/INH;0.0045MG/INH
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
BREYNA	BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE	0.08MG/INH;0.0045MG/INH	AEROSOL, METERED;INHALATION	Prescription	No	AB	211699	MYLAN
SYMBICORT	BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE	0.08MG/INH;0.0045MG/INH	AEROSOL, METERED;INHALATION	Prescription	Yes	AB	021929	ASTRAZENECA

AEROSOL, METERED;INHALATION; 0.16MG/INH;0.0045MG/INH
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
BREYNA	BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE	0.16MG/INH;0.0045MG/INH	AEROSOL, METERED;INHALATION	Prescription	No	AB	211699	MYLAN
SYMBICORT	BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE	0.16MG/INH;0.0045MG/INH	AEROSOL, METERED;INHALATION	Prescription	Yes	AB	021929	ASTRAZENECA

Top